Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients: Retrospective Analysis in a Prospective National Cohort Study (RAL-LT-HIV)

Trial Profile

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients: Retrospective Analysis in a Prospective National Cohort Study (RAL-LT-HIV)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Raltegravir (Primary) ; Abacavir; Emtricitabine; Lamivudine; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors; Tenofovir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms RAL-LT-HIV
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top